Bernie Sanders on the Joe Rogan Experience #1330, fact-checked

What the evidence shows: Sanders' claim that drug companies spent "$4.5 billion...on lobbying and campaign contributions" over 20 years blurs two distinct funding streams into a single figure. Federal lobbying-disclosure data compiled by OpenSecrets shows pharmaceuticals/health products was consistently the top-spending lobbying industry, with cumulative lobbying expenditures in the multi-billion-dollar range over the two decades in question, so the $4.5 billion figure appears to describe lobbying spending alone rather than lobbying plus contributions combined. Campaign contributions from the industry are tracked separately by OpenSecrets and are far smaller: in a later public statement, Sanders himself separated the two categories explicitly, citing $8.5 billion in industry lobbying versus just over $700 million in campaign contributions over a comparable 25-year span, a roughly 12-to-1 ratio that shows lobbying and contributions are normally reported as distinct, unequal sums rather than combined into one total. PolitiFact's review of a related Sanders claim about pharmaceutical lobbying confirmed the industry's lobbying spending was genuinely the largest of any sector, while rating a related lobbyist-count claim only "Half True" for imprecision. The underlying scale of pharmaceutical influence spending is well documented and substantial, but combining lobbying and campaign-contribution totals into a single figure, as this quote does, overstates precision and conflates two categories Sanders elsewhere reports separately.

What the evidence shows: Sanders claimed pharmaceutical companies spent $4.5 billion over the prior 20 years on lobbying and campaign contributions combined. A peer-reviewed JAMA Internal Medicine study of federal and state disclosure data found the pharmaceutical and health-product industry spent $4.7 billion on federal lobbying alone between 1999 and 2018, plus roughly $1.29 billion in campaign contributions to federal and state candidates and committees over the same period, a combined total near $6 billion. Sanders' $4.5 billion figure closely tracks the lobbying-only total for a comparable 20-year window but understates the combined lobbying-and-contributions total the study documents. Separately, a 2021 PolitiFact review of a related but distinct Sanders claim (about the number of pharma lobbyists on Capitol Hill) rated it "Half True" for mixing pharmaceutical lobbyists with lobbyists from other health-product sectors, and reporting on OpenSecrets' methodology shows industry-wide lobbying and contribution totals can be sensitive to how figures are aggregated. Neither of those two sources directly evaluates this specific dollar figure; they are offered as context on how aggregate industry spending claims can be constructed differently. Overall, the order of magnitude in Sanders' claim is well-supported by the best available tracking data for the period, though it describes as a single "lobbying and campaign contributions" total a figure that most closely corresponds to lobbying expenditures alone.

What the evidence shows: Sanders was referring to California's 2016 Proposition 61, a ballot measure that would have limited state drug purchases to prices paid by the U.S. Department of Veterans Affairs. Contemporaneous PolitiFact reporting on campaign finance disclosures shows the "No on Proposition 61" opposition committee, funded largely by pharmaceutical manufacturers, had raised nearly $87 million by early October 2016 and nearly $110 million by November 4, 2016, shortly before the measure was defeated 54%-46% on November 8. Sanders' figure of $131 million exceeds the reported total by roughly $20 million and is not supported by the campaign-finance figures reported at the time. The best available contemporaneous reporting indicates opposition spending closer to $109-110 million rather than $131 million.

What the evidence shows: Sanders references two separate figures: opposition spending on California's 2016 Proposition 61 drug-pricing initiative, and annual profit for the ten largest drug companies. Independent reporting at the time put pharmaceutical industry spending against Prop 61 at roughly $109 million as of early November 2016, rising toward the $120-130 million range by the final pre-election tally, so a $131 million total is in the right neighborhood though not independently confirmed at that exact figure by an allowlisted source here. The '$69 billion' profit figure for the 'top 10 drug companies' is a recurring Sanders talking point: PolitiFact's 2019 fact-check of a related Sanders claim quotes him making this identical $69 billion/top-10 claim but does not itself verify or rate that figure, it treats it as unchecked context while fact-checking only the accompanying '1 in 5 can't afford drugs' statistic. The methodology behind the $69 billion number (which ten companies, profit vs. some other measure) is not transparently sourced in Sanders' public remarks. Overall, the ballot-measure spending figure is roughly consistent with contemporaneous reporting, while the drug-company profit figure is a repeated but unverified stump statistic.

What the evidence shows: Sanders is describing a July 2019 event in which he led a group of Type 1 diabetics from the U.S. to a pharmacy in Windsor, Ontario to buy insulin, at the time citing a roughly $340 U.S. price against roughly $30-$32 in Canada for a comparable vial, close to a ten-to-one ratio for that specific purchase. Government-commissioned research supports the same direction but a smaller average gap: an ASPE (HHS)-funded RAND analysis of 2022 IQVIA pricing data found average U.S. gross insulin prices were more than six times prices in Canada specifically, while the study's 'nearly ten times' figure compares the U.S. average to 33 OECD countries combined, not Canada alone. A prior version using 2018 data found U.S. prices roughly 6.3 times Canada's. The direction of Sanders' claim, that identical insulin is dramatically cheaper in Canada, is well supported, and his specific single-purchase anecdote of a roughly tenfold difference is plausible for that transaction. But generalizing 'one tenth the price' as the typical U.S.-Canada gap overstates the government's own average figure, which is closer to a sixfold difference.

What the evidence shows: Sanders' figure matches CMS's own historical baseline for Medicare enrollment. CMS's "Medicare and Medicaid by the Numbers" fact sheet states 62.7 million Americans were enrolled in Medicare in 2024, 'up from 19 million when the program began.' A separate CMS retrospective, 'Medicare & Medicaid: Then & Now,' likewise lists Medicare enrollment as 19 million seniors (1 in 10 Americans) at the program's start, versus 68 million beneficiaries today. CMS's official history page confirms President Johnson signed the law creating Medicare and Medicaid on July 30, 1965. CMS's materials describe 19 million as the initial enrollment figure but do not break out whether that count reflects people who actively signed up versus those automatically covered through Social Security records, so Sanders' framing that they "signed up" is a reasonable but slightly imprecise gloss on the official figure. Overall, the core number Sanders cites is well-supported by CMS's own retrospective data.

What the evidence shows: Sanders has used versions of this "$21 trillion gain for the top 1%, $900 billion decline for the bottom half" statistic repeatedly since around 2019, typically attributing it to Federal Reserve wealth data. The Federal Reserve's Distributional Financial Accounts (DFA), compiled from the Survey of Consumer Finances, do show a real and well-documented trend: the top 1%'s share of total U.S. household wealth has risen substantially since the late 1980s/early 1990s, while the bottom 50%'s share has remained a small, sometimes-declining fraction of total wealth (roughly 1-3% of aggregate net worth in most years). However, the specific paired figures Sanders cites do not correspond cleanly to any single published Federal Reserve table for a fixed 30-year window; the bottom half's aggregate wealth in nominal dollars has generally risen over most 30-year spans (not declined by $900 billion), even though its wealth share has stagnated or fallen and its wealth is heavily concentrated in home equity and vulnerable to shocks like the 2008 crash. The $21 trillion figure for top-1% gains is roughly in the plausible range depending on the exact start/end dates chosen, since top-1% wealth has grown by tens of trillions of dollars in various multi-decade windows, but Sanders and other progressive politicians (including Elizabeth Warren, who cited similar figures) have used varying timeframes and slightly different numbers across speeches, making the claim difficult to verify as a single precise fact rather than an approximate, cherry-picked framing of real underlying Fed data. The overall direction, sharply rising wealth concentration at the top since the late 1980s, is well supported by Federal Reserve data; the specific dollar figures and the claim of an outright dollar decline for the bottom half are not clearly substantiated and are best characterized as an imprecise, rounded talking point built on real but loosely applied statistics.

What the evidence shows: Sanders has repeated versions of this wealth-concentration claim for years, with the exact comparison group varying (bottom 90%, 92%, or half of Americans). Federal Reserve Distributional Financial Accounts data, which combine aggregate balance-sheet figures with the Survey of Consumer Finances, has for several years shown the top 1% of U.S. households holding roughly 30% or more of total household net worth, a share comparable to or exceeding that held by the bottom 90%. PolitiFact has separately rated closely related formulations of this claim (top 0.1% versus bottom 90% in 2015, and three richest Americans versus the bottom half in 2019) as Mostly True and True, based on Federal Reserve and Saez-Zucman/Forbes-derived wealth data. Economists have flagged some methodological caveats, including that these net-worth measures count debt as negative wealth (which can understate the position of people with high future earning potential but current student or mortgage debt) and, in some versions, exclude Social Security wealth, but no independent fact-check found the underlying top-1%-vs-most-of-the-rest comparison to be false or fabricated. The specific "bottom 92%" figure is a minor variant of the more commonly cited "bottom 90%" statistic and is directionally consistent with it.

What the evidence shows: Sanders' figures match a June 2019 analysis by policy researcher Matt Bruenig (People's Policy Project) of the Federal Reserve's then-newly released Distributional Financial Accounts (DFA) data, which has tracked U.S. household wealth by percentile group quarterly since Q3 1989. That analysis found the top 1%'s net worth rose by about $21 trillion while the bottom 50%'s net worth fell by about $900 billion between 1989 and late 2018, a span matching Sanders' 30-year framing. The Federal Reserve's own DFA series, confirmed live on its site, is the underlying dataset used for that calculation, though the Fed does not publish the $21 trillion / $900 billion figures itself as a standalone headline statistic; they were derived by an outside researcher from the Fed's public data. The direction and rough scale are consistent with the Fed's official percentile-level wealth series, which shows the top 1%'s wealth share rising substantially since 1989 while the bottom half's share has stayed near or below zero. A separate, related Sanders wealth-inequality claim drawing on Federal Reserve data was rated True by PolitiFact, which described Federal Reserve wealth data as a gold-standard source documenting a widening wealth gap.

What the evidence shows: Sanders is repeating a widely circulated media framing of the IPCC's October 2018 Special Report on Global Warming of 1.5C, commonly summarized in headlines as "12 years to save the planet." The report itself does not set a 12-year hard deadline after which damage becomes irreparable; instead it finds that, to have a reasonable chance of limiting warming to 1.5C, global net CO2 emissions would need to fall about 45% from 2010 levels by 2030 and reach net zero around 2050, with impacts worsening progressively as warming rises toward and beyond 1.5C and 2C. The "12 years" figure came from the gap between the report's 2018 publication and 2030, the interim milestone in these emissions pathways, and was popularized by contemporaneous press coverage rather than stated as a point-of-no-return by the IPCC itself. Climate scientists and journalists have pushed back on the deadline framing, noting that warming and its risks are continuous and cumulative: every increment of additional warming increases risk, there is no single year at which damage flips from reversible to irreversible, and delaying action past 2030 makes the 1.5C goal harder but does not itself trigger sudden irreparable damage. The claim as stated distorts a real and well-supported scientific finding (steep, urgent emissions cuts are needed this decade) into an inaccurate description of what the IPCC said.

What the evidence shows: Sanders claimed the United States pays roughly ten times more than Canada and other countries for insulin and for prescription drugs broadly. For insulin specifically, this figure is in the right range for list/gross prices: a RAND analysis using 2022 data found U.S. gross insulin prices averaged 9.71 times those in 33 comparison OECD countries, and roughly six times Canada's prices specifically, though after accounting for manufacturer rebates the U.S.-versus-comparison-country gap narrows to about 2.3 times. For prescription drugs overall, the ratio is considerably smaller than tenfold: the same RAND research found U.S. prices averaged 2.78 times those in 33 other countries across all drugs, with brand-name drugs at 4.22 times and unbranded generic drugs, which make up the large majority of U.S. prescriptions by volume, actually priced lower in the U.S. than in comparison countries. The claim is well-supported for insulin's gross list-price ratio but overstates the situation when generalized to 'other drugs' as a whole, where the average gap is closer to threefold than tenfold.

What the evidence shows: Sanders cited a Tax Policy Center finding that by 2027, roughly 83% of the benefits of the 2017 Tax Cuts and Jobs Act would flow to the top 1% of households, and this figure is accurate as a description of that specific year. However, the 83% figure is not representative of the law's overall 10-year effect: it is driven almost entirely by the fact that most individual income tax cuts were written to expire by 2025 (for budget-reconciliation reasons), while the corporate tax cut, which benefits higher earners more, was made permanent. In earlier years the top 1% share was much lower (about 20.5% in 2018 and 25.3% in 2025, per Tax Policy Center data cited by PolitiFact), and most households received a tax cut in those years, unlike the projected 2027 outcome where households earning under roughly $155,000 would see no cut at all on average. FactCheck.org explicitly names Sanders among the Democrats using this "83 percent... at the end of 10 years" line and, along with PolitiFact, characterizes it as technically accurate for the single year cited but misleading when presented as a general description of who benefits from the tax law overall; PolitiFact rated a similar DNC claim using the same figure Half True on these grounds.

What the evidence shows: Sanders made this claim on JRE #1330, recorded around August 2019. Amazon's own SEC filings showed it owed $0 in federal income tax on U.S. profits in both 2017 and 2018, a year in which it earned $11.2 billion in pre-tax U.S. income and reported a federal tax rebate of roughly $129 million; this was independently confirmed by tax analysts and multiple fact-checking organizations and stemmed from legal use of stock-compensation deductions, R&D credits, and other tax breaks rather than illegal evasion. Amazon began paying federal income tax again starting with the 2019 tax year. The $150 billion net-worth figure for Bezos was accurate as a snapshot -- Bloomberg and Forbes indices put his wealth above $150 billion for stretches of 2018 into mid-2019 -- but such wealth estimates fluctuate with stock price and, in Bezos's case, were reduced by roughly a quarter after his 2019 divorce settlement, so the figure is better read as a rough point-in-time estimate than a fixed or permanent state. Overall, the tax claim is well-supported for the years in question, while the wealth figure is an imprecise but roughly accurate approximation for the period.

What the evidence shows: Sanders has repeatedly paired his college-affordability and student-debt-cancellation proposals with a financial transaction tax he says will more than cover the cost, but independent analysts have consistently produced far lower revenue estimates than the figures Sanders cites. When Sanders made a similar pairing in 2016 (a roughly $50 billion/year free-tuition plan funded largely by a Wall Street tax), the nonpartisan Tax Policy Center put the tax's yearly yield at only $50-60 billion, versus the more than $300 billion figure Sanders relied on -- PolitiFact attributed the gap largely to differing assumptions about which trades are taxed and how trading volume would respond. A similar gap shows up in other Democrats' financial-transaction-tax proposals: the Congressional Budget Office estimated a 0.1% tax would raise about $777 billion over ten years (roughly $78 billion/year), a small fraction of the roughly $240 billion/year implied by Sanders's $2.4 trillion, ten-year figure. Because transaction-tax revenue estimates hinge heavily on assumptions about how much trading volume shrinks in response to the tax, economists and fact-checkers have found no consensus that a Wall Street speculation tax at the scale Sanders describes would raise anywhere near the $2.4 trillion he cites, making the clean $2.2 trillion cost matched by $2.4 trillion in revenue an unverified and likely overstated pairing rather than an established fact.

What the evidence shows: There is no official U.S. count of civilian-owned firearms, so estimates vary by methodology, but Sanders' figures fall within the range of credible estimates rather than being contradicted by them. On total guns, The Trace's ongoing analysis of ATF manufacturing, import, and export data, applying economist Philip Cook's standard 1% annual attrition rate for guns falling out of circulation, arrives at approximately 403 million guns in circulation, closely matching Sanders' approximately 400 million figure. Other rigorous estimates diverge: the Small Arms Survey put U.S. civilian-held firearms at 393 million as of 2017, while the Harvard/Northeastern National Firearms Survey, using owner-reported data, estimated a considerably lower 265 million in 2015. On assault weapons, there is no standardized legal or statistical definition, which is why estimates for that subset vary widely. PolitiFact fact-checked this same Sanders claim, made publicly around the time of this August 2019 episode, and rated it Half True, concluding that the 5 to 10 million figure is likely conservative (i.e., a plausible floor rather than an inflated number) but that no official count of assault-style weapons exists in either civilian or military hands. Overall, both figures are within the range of credible, if imprecise, estimates.

What the evidence shows: The 1994 Violent Crime Control and Law Enforcement Act (Public Law 103-322) banned the manufacture and sale of specified semiautomatic weapons and large-capacity magazines, and Sanders is correct that the ban ran for 10 years. However, the law contained a built-in 10-year sunset clause, meaning it was written to expire automatically in September 2004 unless Congress affirmatively renewed it; Congress never voted to repeal it. When the ban lapsed on September 13, 2004, the Republican-controlled Congress and President George W. Bush did not hold a vote to extend it, and reauthorization efforts, including one led by Senator Dianne Feinstein, failed to gain sufficient support to pass. Fact-checkers have specifically corrected the related but distinct claim that Bush "lifted" or repealed the ban, noting that he stated he would sign an extension if Congress sent him one but did not push lawmakers to act. Characterizing the ban as having been actively "undone" overstates what happened: it expired through inaction on renewal rather than through a repeal vote.

What the evidence shows: This episode (JRE #1330) aired around August 2019. At that time, Forbes' tracking of the world's richest person, Jeff Bezos, put his net worth at roughly $114-115 billion (as of September 2019), well below the $155 billion figure cited, and down from a roughly $131 billion peak reported in March 2019 before his divorce settlement reduced his Amazon stake. Bezos's wealth did not reach $155 billion until later; it crossed $200 billion only in August 2020. Notably, elsewhere in this same interview Sanders cites the same billionaire's wealth at $150 billion, suggesting the $155 billion figure reflects imprecise rounding rather than a distinctly sourced data point. On military spending, the fiscal year in effect when this episode aired (FY2019) carried a national-defense topline in the roughly $700s-billion range; the next authorization, the $738 billion FY2020 National Defense Authorization Act, was not signed into law until December 17, 2019, months after this interview, and even that figure falls short of the $750 billion Sanders cites. Both figures Sanders gives are higher than the documented totals for the relevant period, though they are in the correct order of magnitude and became closer to accurate for later fiscal years and billionaire net-worth peaks.

What the evidence shows: Sanders' 87 million figure closely resembles other large healthcare-access statistics he has cited around this period, including a similar 85 million figure. PolitiFact traced that 85 million claim to a Commonwealth Fund analysis finding 43% of working-age adults, uninsured or underinsured, and rated it defensible only when underinsured people (not just the uninsured) are counted. That reporting indicates Sanders' large healthcare-access numbers are typically built by combining multiple categories, such as uninsured plus underinsured or people who delayed care due to cost, rather than reflecting a single direct measure of people who literally cannot see a doctor. No source directly verifies an 87 million figure specifically, so this should be read as a plausible order-of-magnitude estimate assembled from combined survey categories rather than a precise, singularly-sourced statistic.